6-bromo-D-6-deoxy-galactose | 18465-33-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-bromo-D-6-deoxy-galactose
• 英文别名: (2R,3S,4R,5S)-6-bromo-2,3,4,5-tetrahydroxyhexanal
• CAS: 18465-33-3
• 化学式: C₆H₁₁BrO₅
• 分子量: 243.054
• InChiKey: GGVVBDUYWFUSBV-DPYQTVNSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  双丙酮半乳糖 生成 6-bromo-D-6-deoxy-galactose
  参考文献：
  名称：

  碳水化合物与亚磷酸三苯甲硫醇及相关化合物的反应：脱氧糖的新合成

  摘要：

  提出了亚磷酸三苯酯甲硫醇和相关化合物作为用卤素原子代替被保护的碳水化合物的羟基的试剂。取代反应的难易程度取决于羟基对S N 2攻击的空间可及性。异亚丙基和亚苄基以及酯保护基团可以在反应条件下迁移。讨论了这些迁移的可能机制。结果，已经开发了从部分甲基化或甲苯磺酸化的单糖开始的脱氧糖的新途径。

  DOI：

  10.1016/s0040-4020(01)99352-4

文献信息

• METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION
  申请人：Seattle Genetics, Inc.

  公开号：US20140031536A1

  公开（公告）日：2014-01-30

  The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.

  这项发明提供了一种减少核心岩藻糖基化的抗体和抗体衍生物制备的方法和组合物。
• Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
  申请人：SEATTLE GENETICS, INC.

  公开号：US10443035B2

  公开（公告）日：2019-10-15

  The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.

  本发明提供了制备核心岩藻糖基化减少的抗体和抗体衍生物的方法和组合物。
• MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS
  申请人：Interstitial Therapeutics

  公开号：EP1789030A2

  公开（公告）日：2007-05-30
• MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS
  申请人：Interstitial Therapeutics

  公开号：EP1789107A2

  公开（公告）日：2007-05-30
• SUGAR KINASES WITH EXPANDED SUBSTRATE SPECIFICITY AND THEIR USE
  申请人：THORSON S. Jon

  公开号：US20050208633A1

  公开（公告）日：2005-09-22

  One preferred embodiment of the present invention provides a GalK variant comprising a Y371H, M173L or Y371H-M173L mutation for in vivo and in vitro glycorandomization. In another preferred embodiment, the E. coli GalK variant is mutated at one or more amino acids including R28, E34, D37, D174, Y233, C339, Y371, Y371H, M173, M173L and C353. The GalK variants display catalytic activity toward a variety of D or L sugars. Another preferred embodiment provides method of phosphorylating sugars comprising the step of incubating a nucleotide triphosphate (NTP) and a D or L sugar in the presence of a GalK variant such that a sugar phosphate is produced. This sugar phosphate may be further incubated with a nucleotidylyltransferase, such that a NDP-sugar is produced. The NDP-sugar may be further incubated with a biomolecule capable of being glycosylated in the presence of a glycosyltransferase, such that a glycosylated biomolecule is produced.